Mepolizumab and dupilumab show no significant difference in reducing exacerbations in COPD patients with eosinophilic phenotype
A matching-adjusted indirect comparison (MAIC) of three mepolizumab trials (METREX, METREO, MATINEE) and two dupilumab trials (BOREAS, NOTUS) found no statistically significant differences between the two biologics in reducing moderate/severe exacerbations or improving health-related quality of life (SGRQ-C) in COPD patients with eosinophilic phenotype. The rate ratio for annualized moderate/severe exacerbations was 0.91 (95% CI: 0.60-1.37) using investigator-assessed chronic bronchitis and 1.13 (95% CI: 0.80-1.58) using SGRQ-C definition, both non-significant.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Mepolizumab and dupilumab show no significant difference in reducing exacerbations in COPD patients with eosinophilic phenotype The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 53/100 (low).
The Claim
Mepolizumab and dupilumab show no significant difference in reducing exacerbations in COPD patients with eosinophilic phenotype
This conclusion is most relevant to: Patients with COPD and eosinophilic phenotype (blood eosinophils ≥300 cells/μL, mMRC ≥2, moderate-to-severe airflow limitation, chronic bronchitis).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Mepolizumab and Dupilumab Show No Significant Difference in Reducing Exacerbations in Patients with COPD and an Eosinophilic Phenotype: Matching-Adjusted Indirect Treatment Comparison. (Chest, 2026) —
How It Works
The proposed biological pathway:
- ▸Both mepolizumab and dupilumab target type 2 inflammation pathways (IL-5 and IL-4/IL-13, respectively)
- ▸MAIC reweighted individual patient data from mepolizumab trials to match aggregate baseline characteristics of dupilumab trials
- ▸Patients were matched on restrictive eligibility criteria (eosinophil count, mMRC, airflow limitation, chronic bronchitis)
- ▸No statistically significant difference in exacerbation reduction or quality of life improvement was observed
Who Might Benefit
Evidence fit by population:
- ▸Patients with COPD and eosinophilic phenotype (blood eosinophils ≥300 cells/μL, mMRC ≥2, moderate-to-severe airflow limitation, chronic bronchitis)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Indirect comparison, not a head-to-head randomized trial; potential residual confounding despite matching
- ▸Matching was based on aggregate data from dupilumab trials, which may not capture all patient-level characteristics
- ▸Chronic bronchitis definition varied (investigator-assessed vs SGRQ-C), leading to different patient subsets and results
Frequently Asked Questions
What is the main finding of this study?▼
The study found no statistically significant difference between mepolizumab and dupilumab in reducing moderate/severe exacerbations or improving quality of life in COPD patients with eosinophilic phenotype.
How was the comparison made?▼
The comparison was made using a matching-adjusted indirect comparison (MAIC), which reweighted individual patient data from mepolizumab trials to match the aggregate baseline characteristics of dupilumab trials.
What were the inclusion criteria for patients in this analysis?▼
Patients had COPD with blood eosinophil counts ≥300 cells/μL, mMRC grade ≥2, moderate-to-severe airflow limitation, and chronic bronchitis (defined by investigator or SGRQ-C).
What are the implications for clinical practice?▼
The results suggest that either mepolizumab or dupilumab may be used as add-on therapy for COPD with eosinophilic phenotype, with no clear efficacy advantage of one over the other based on this indirect comparison.
References
- 1.Bourbeau J, Min J, Kolterer S, Yang S, Hunger M, Wang X, Sciurba FC. “Mepolizumab and Dupilumab Show No Significant Difference in Reducing Exacerbations in Patients with COPD and an Eosinophilic Phenotype: Matching-Adjusted Indirect Treatment Comparison..” Chest, 2026. PMID: 42617837 DOI: 10.1016/j.chest.2026.07.5242